Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Antimicrobial peptides stage a comeback

Nature Biotechnology volume 31, pages 379–382 (2013)Cite this article

Subjects

A Correction to this article was published on 01 December 2013

This article has been updated

Better understanding of the mechanisms of action, modification and synthesis of antimicrobial peptides is reigniting commercial development. Jeffrey L. Fox reports.

Against a background of US federal government incentives providing additional years of market exclusivity for antimicrobials (Box 1) and a more flexible stance at the US Food and Drug Administration (FDA) with respect to clinical trial design, efforts to bring antimicrobial peptides into clinical use are accelerating. Unlike the exuberance accompanying forays into antimicrobial peptide development a decade ago, current optimism is tempered by fuller recognition of the challenges in translating R&D leads into a new class of products.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

Figure 1: Antimicrobial peptides take shape.

Change history

  • 27 June 2013

    In the version of this article initially published, the Italian company researching the use of novel antibiotics was erroneously identified as NeED Pharmaceuticals. The company’s name is NAICONS.

  • 01 December 2013

    In the May 2013 news analysis “Antimicrobials stage a comeback” (Nat. Biotechnol. 31, 379–382, 2013), the Italian company researching the use of novel antibiotics was erroneously identified as NeED Pharmaceuticals. The company's name is NAICONS. The error has been corrected in the PDF and HTML versions of this article.

Author information

Affiliations

  1. Washington, DC

    Jeffrey L Fox

Authors
  1. Jeffrey L Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fox, J. Antimicrobial peptides stage a comeback. Nat Biotechnol 31, 379–382 (2013). https://doi.org/10.1038/nbt.2572

Download citation

Further reading

Search

Advanced search

Quick links